{"name":"Myovant Sciences GmbH","slug":"myovant-sciences-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Estradiol/norethindrone acetate","genericName":"Estradiol/norethindrone acetate","slug":"estradiol-norethindrone-acetate","indication":"Moderate to severe vasomotor symptoms associated with menopause","status":"marketed"},{"name":"Placebo for relugolix","genericName":"Placebo for relugolix","slug":"placebo-for-relugolix","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Estradiol/norethindrone acetate","genericName":"Estradiol/norethindrone acetate","slug":"estradiol-norethindrone-acetate","phase":"marketed","mechanism":"Estradiol and norethindrone acetate work together as a hormone replacement therapy, with estradiol providing estrogen and norethindrone acetate providing progestin to supplement declining hormones.","indications":["Moderate to severe vasomotor symptoms associated with menopause","Moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause"],"catalyst":""},{"name":"Placebo for relugolix","genericName":"Placebo for relugolix","slug":"placebo-for-relugolix","phase":"phase_3","mechanism":"A placebo control contains no active pharmaceutical ingredient and serves as a comparator in clinical trials to establish the efficacy of relugolix.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNSkdoMEs5aUNKNmhGM25Ec1lXQkRfTkNUYWEtZGNlTElhTlFCZWY0VzlFRndUbjcxVjZiQUpMdGRZd3lUR0o5Y1BEeDhlbzZTdmI2cjIyak9vUjdBTFpMUlA2eGZhR205VncyRG1IQ1BFT2luNm9wTEFRV3Z4V1hUTVdmNDFNeVk0LS03Nkx3?oc=5","date":"2025-05-28","type":"pipeline","source":"Fortune Business Insights","summary":"Prostate Cancer Hormone Therapy Market Size, Share [2034] - Fortune Business Insights","headline":"Prostate Cancer Hormone Therapy Market Size, Share [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOY3NfX1kwS0gwUHhPNEY2cnhINUxhZXQ4eE5SaTNYSWs1N1dpajdCU3ZVVm9FSEFZckF2YlZmREhjWHZoVXVEMHhvNWhOSnBjTmpMS00xVm9YXzdOR3BLTkdadVhBemREMW9YUGg1ZUxVRWMyeUdkRE1FYVY0RkJ4ZVByWlVXQXdQVUk5Y1RFUmtLR1BUam1qbXhwZ0NRaWVDWVNIeThhSmphU2gtWVhTWnBCSEw?oc=5","date":"2025-05-21","type":"pipeline","source":"Fortune Business Insights","summary":"METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THERAPEUTICS MARKET TRENDS - Fortune Business Insights","headline":"METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THERAPEUTICS MARKET TRENDS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOYTBoU3QwLVE1eGtZSDJ6SFhGbTBsTkpMaXJTSWg4Q0VzVmgzYXhIZm9vUWZzUnlRRTM1RWhzNE1Uck1WSjhKVEhwMW9xNEp6M2xFZ2dib0toUFNsTm11WV8tT2kxV1RfUFQ3ODVXOWRWeE9VN3dVTXVfVmtISXo1eHBBVnBKMDRtdkE?oc=5","date":"2025-04-11","type":"pipeline","source":"Fortune Business Insights","summary":"Prostate Cancer Therapeutics Market Size, Share, Trends [2034] - Fortune Business Insights","headline":"Prostate Cancer Therapeutics Market Size, Share, Trends [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE9zSWc4QWY3UW53Q1BYNTB3bXVISHdLZVVPcGIyb2RWY0hmM2s3OEtJeHdDcTB2ajVsYWZXRnRUOGdaMGU1UmhlelVZVnpxUmJIN2JaelFUTjJ1aVp1b3puSE9zeE4yTWNqNzFKc0lRS05XUFhD?oc=5","date":"2024-11-18","type":"pipeline","source":"tandfonline.com","summary":"Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer - tandfonline.com","headline":"Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxOY2piZ0NfTnBXRzBKdFdWWXRZTmpjWm9aSHpyRjJrMzA4alZ4R05xeHdMTWFRc3pxWmpEQWw0UlJSaURVTDNTS0tFUVRoQWhMTldIcDlxdG0zZDN6WXk3b0VVWlFtaV9kNVg5VEJUVkR2aF9QbzR5cVIxekU4b0h2ZlhDNXJUVlRSOVlSam0xSERvS25ZN1dWb0pCdGRIU2VhaUlGUXBIWHVwZTk0enh3dGdBd0RaZ0FRM0NWMXNGXzM4cnFWbGpPNzZTVElTS0RwYmxlQTQwUzJTT1lmYTdseUlpVnhMWGdmZ3lhVlhB?oc=5","date":"2023-01-24","type":"pipeline","source":"Insideradio.com","summary":"Strong Showings For Financial Services, Medical/Pharma In Latest Spot Count. - Insideradio.com","headline":"Strong Showings For Financial Services, Medical/Pharma In Latest Spot Count.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNbnFrNU1VTWlUdS02emphXzRqVzRWLWVDVnZoTEZTMFRjR0tkaU1JTmJyZWNuUnN1WHRnaVRSRmkzMW85NF9lTkdrcWxtdkxuUEZwbTI4TzVjWC1nWVdLMzR6UkF4WXA4Zm9jclNBVGYwR0NZT3hhdHZCVHB1RjdzZ0xPa19pNkhKN3l1NE8tMTZ0ZVBvV3d0TkNhRlppcHpfdTdDS1ZRTWdRcGh3REVCc0dhUWFFWEFfUUdRblBmNnYtLXdl?oc=5","date":"2022-08-15","type":"pipeline","source":"European Medical Journal","summary":"Improvements in Prostate Cancer Management: Focus on Imaging and Treatment - European Medical Journal","headline":"Improvements in Prostate Cancer Management: Focus on Imaging and Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPYXNXdm0xWU5wWEZGV3c1aWl6OGxRTnlweHllb3Q1Z09qMzlnbUNfaXNIU2I4TDVZRGtkdlI5Q2IzSmlibGtVWjVnZXg5ZGxxc0ZWYlA4NHVRUHc2RzRyQWhIemY1RWp3N3RwZkt0SUYtYVpvN1lITEg0aTNvSUpaOFBlV3pMOEd5Rk03VjBQY192MWNfaUQxNG1URXJUNF9Qc2NmenlUZnpIbDNMaVFlZmU0amlBa2xQeWl4Sml3aUJBSldSalE?oc=5","date":"2022-08-11","type":"regulatory","source":"BioWorld News","summary":"Women with endometriosis have new treatment option with FDA approval of Myfembree sNDA - BioWorld News","headline":"Women with endometriosis have new treatment option with FDA approval of Myfembree sNDA","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5sdXZpUmNIYy16TzN0bmxKaEV0eVZxR1haTXdNN2VCNXkzbXpNQWRyNGpnMmN1cW1IQm9ZZ2JGSFhzVDB3aVQ2Q0JHTW9wdmhnV0NTN2FFRkdLUWl6OHMzTDk0MjQ3WHQzUmd3ZA?oc=5","date":"2019-06-15","type":"pipeline","source":"Market.us","summary":"Hormone Replacement Therapy Market Size | CAGR 6.7% - Market.us","headline":"Hormone Replacement Therapy Market Size | CAGR 6.7%","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}